Speciality
Spotlight

 




 


Oncology


 

 





Experimental
Stem Cell Transplant

   

  • De
    Fabritiis P, Petti MC, Montefusco E, et al [ Universita
    “La Sapienza” Rome, Istituto Regina Elena,
    Rome; Lynx Therapeutics Inc, Hayward, Calif; et al ]

    BCR-ABL Antisense Oligodeoxynucleotide in Vitro
    Purging and Autologous Bone Marrow Transplantation for
    Patients with Chronic Myelogenous Leukemia in Advanced
    Phase


    Blood 91: 3156-3162, 1998

      

    The Philaldephia chromosome [BCR-ABL complex] of
    patients with CML] has unveiled many of the pathogenic
    mechanisms. Its antisense oligodeoxynucleotides [ODN]
    have an antileukemia effect, documented so far in vitro
    studies. This study of 8 patients with CML autografted
    in an advanced disease stage were purged in vitro with
    junction-specific [J-sp] BCR-ABL antisense ODN at the
    time of transformation in accelerated phase or during
    second chronic phase. Two patients had a complete
    karyotypic response and other 6 had minimal or no
    response. This type of bone marrow purging and autograft
    mediated by ODN has low toxicity satisfactory
    haematopoietic reconstitution. The editor comments that
    the authors could bring about a meaningful clinical
    effect by the above study a clinical effect at stage of
    CML that is usually refractory to any standard therapy.
    Antisense strategies have also been developed in other
    malignant diseases for example, targeting mutated p53
    genes.

         


 

 



 

 

Speciality Spotlight

 

 

Experimental Stem Cell Transplant
   

  • De Fabritiis P, Petti MC, Montefusco E, et al [ Universita “La Sapienza” Rome, Istituto Regina Elena, Rome; Lynx Therapeutics Inc, Hayward, Calif; et al ]
    BCR-ABL Antisense Oligodeoxynucleotide in Vitro Purging and Autologous Bone Marrow Transplantation for Patients with Chronic Myelogenous Leukemia in Advanced Phase
    Blood 91: 3156-3162, 1998
      
    The Philaldephia chromosome [BCR-ABL complex] of patients with CML] has unveiled many of the pathogenic mechanisms. Its antisense oligodeoxynucleotides [ODN] have an antileukemia effect, documented so far in vitro studies. This study of 8 patients with CML autografted in an advanced disease stage were purged in vitro with junction-specific [J-sp] BCR-ABL antisense ODN at the time of transformation in accelerated phase or during second chronic phase. Two patients had a complete karyotypic response and other 6 had minimal or no response. This type of bone marrow purging and autograft mediated by ODN has low toxicity satisfactory haematopoietic reconstitution. The editor comments that the authors could bring about a meaningful clinical effect by the above study a clinical effect at stage of CML that is usually refractory to any standard therapy. Antisense strategies have also been developed in other malignant diseases for example, targeting mutated p53 genes.
         

 

 

 

By |2022-07-20T16:43:54+00:00July 20, 2022|Uncategorized|Comments Off on Experimental Stem Cell Transplant

About the Author: